Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Uniphar PLC (UPR – Research Report) and keeping the price target at €4.60.
Christian Glennie has given his Buy rating due to a combination of factors that highlight Uniphar PLC’s strong financial performance and growth prospects. The company has demonstrated impressive financial results for FY24, with significant growth in both the Pharma and Medtech divisions, leading to a 9.6% increase in group gross profit. This growth, coupled with a solid EBITDA target of €200 million by 2028 and a €35 million share buy-back initiative, underscores Uniphar’s confident outlook.
Moreover, Uniphar is trading at a relatively low valuation of 6.5x 2025 EV/EBITDA compared to its peers, which typically trade at over 10x. This suggests that the stock is fundamentally mispriced, offering a potential upside of 89.3% to the price target. The company’s strong track record, with a 15% five-year EPS CAGR and organic growth prospects of approximately 11% EPS CAGR from 2024 to 2028, further supports the Buy rating. As a top pick in its sector, Uniphar is well-positioned to meet current market expectations and continue its growth trajectory.
According to TipRanks, Glennie is an analyst with an average return of -11.5% and a 31.43% success rate.